Corinne Bright , PhD

Associate
Menlo Park, CA

2005 Grube Fellow
Corinne Bright received her B.S. degree in Engineering with an emphasis in Biology from Swarthmore College in 1998. She received her Ph.D. in Biomedical Engineering from Johns Hopkins University, where her thesis work focused on developing a platform for drug and nonviral gene delivery to treat spinal cord injury. To that end, Corinne designed a novel injectable thermoreversible gel for the dual delivery of a therapeutic peptide and plasmid DNA to stimulate motor neuron regeneration in the adult rat spinal cord. She also lead collaborations with the Neurology, Ophthalmology, and Orthopaedics Departments at Johns Hopkins, the Bioengineering Dept at University of Washington, and Molecular Pharmacology Dept at Stanford University. These projects ranged from microsphere-based growth factor delivery for optic tract regeneration, to nanosphere-based peptide delivery for the treatment of cardiac ischemia, to gel-based steroid delivery for the treatment of macular degeneration. Corinne worked with surgeons and post-doctoral fellows from conceptualization though animal studies on a nonviral gene delivery system for spine fusion. She joined the privately-held company, Talima Therapeutics, in 2005, heading up the research and development of a drug-device combination product from concept to clinical trials for the treatment of onychomycosis. She is currently a venture associate in the medical device investment team at ONSET Ventures.